These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 16050407)

  • 21. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 26. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-Angiotensin system blockade for diabetic nephropathy prevention.
    Naviglio S; Pirozzi F
    Am J Cardiol; 2010 May; 105(10):1505. PubMed ID: 20451706
    [No Abstract]   [Full Text] [Related]  

  • 29. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K; Jacobsen P; Pietraszek L; Parving HH
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
    Gentile G; Remuzzi G; Ruggenenti P
    Nephron; 2015; 129(1):39-41. PubMed ID: 25531311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The renin-angiotensin-aldosterone system -- more complex as previously thought].
    Wolf G
    Med Klin (Munich); 2005 Aug; 100(8):471-7. PubMed ID: 16096728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and their combination on microalbuminuria in normotensive patients with type 2 diabetes.
    Atmaca A; Gedik O
    Adv Ther; 2006; 23(4):615-22. PubMed ID: 17050503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 36. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 37. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
    J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.